ResMed Steps Up PAP Innovation With New Amalfi vs. CLA11 Sleep Apnea Study

robot
Abstract generation in progress

ResMed (RMD) is conducting a clinical study to compare its new Amalfi platform with the CLA11 platform for treating obstructive sleep apnea. The trial aims to evaluate the performance, comfort, and usability of these PAP systems in home settings to refine future product development. Although currently in the “not yet recruiting” phase, the study indicates ResMed’s continued focus on innovation in its core sleep apnea franchise to potentially gain market share and enhance pricing power.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin